TY - JOUR
T1 - Opioid Prescribing for Osteoarthritis
T2 - Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons
AU - Schnitzer, Thomas J.
AU - Robinson, Rebecca L.
AU - Viktrup, Lars
AU - Cappelleri, Joseph C.
AU - Bushmakin, Andrew G.
AU - Tive, Leslie
AU - Berry, Mia
AU - Walker, Chloe
AU - Jackson, James
N1 - Funding Information:
Thomas J Schnitzer reports clinical research study support (Pfizer, Lilly, Regeneron, Galapagos, Taiwan Liposome Corporation, Anika Therapeutics) and fees for consultancy/advisory boards (Pfizer, Lilly, GSK, AstraZeneca, Galapagos, Merck). Rebecca L Robinson and Lars Viktrup are employees and stockholders of Eli Lilly and Company. Andrew Bushmakin, Joseph C Cappelleri, and Leslie Tive are employees of Pfizer Inc. with stock and/or stock options. Mia Berry, Chloe Walker, and James Jackson are employees of Adelphi Real World, which received funding from Pfizer Inc. and Eli Lilly and Company to conduct the study.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/1
Y1 - 2023/1
N2 - Opioids are often prescribed for osteoarthritis (OA) pain, despite recommendations to limit use due to minimal benefits and associated harms. This study aimed to assess physicians’ practice patterns and perceptions regarding opioids by specialty one year following the Centers for Disease Control and Prevention (CDC) published guidance on opioid prescribing. The 139/153 (90.8%) physicians who reported prescribing opioids in the previous year reported decreased prescribing for mild OA (51.3%, 26.5% and 33.3% of primary care physicians, rheumatologists, and orthopaedic surgeons, respectively), moderate OA (50.0%, 47.1% and 48.1%) and severe OA (43.6%, 41.2% and 44.4%). Prescribing changes were attributed to the CDC guidelines for 58.9% of primary care physicians, 59.1% of rheumatologists, and 73.3% of orthopaedic surgeons. Strong opioids were mostly reserved as third-line treatment. Although treatment effectiveness post-CDC guidelines was not assessed, perceptions of efficacy and quality of life with opioids significantly differed across specialties, whereas perceptions of safety, convenience/acceptability and costs did not. Physicians generally agreed on the barriers to opioid prescribing, with fear of addiction and drug abuse being the most important. Across specialties, physicians reported decreased opioid prescribing for OA, irrespective of OA severity, and in most cases attributed changes in prescribing to the CDC guideline.
AB - Opioids are often prescribed for osteoarthritis (OA) pain, despite recommendations to limit use due to minimal benefits and associated harms. This study aimed to assess physicians’ practice patterns and perceptions regarding opioids by specialty one year following the Centers for Disease Control and Prevention (CDC) published guidance on opioid prescribing. The 139/153 (90.8%) physicians who reported prescribing opioids in the previous year reported decreased prescribing for mild OA (51.3%, 26.5% and 33.3% of primary care physicians, rheumatologists, and orthopaedic surgeons, respectively), moderate OA (50.0%, 47.1% and 48.1%) and severe OA (43.6%, 41.2% and 44.4%). Prescribing changes were attributed to the CDC guidelines for 58.9% of primary care physicians, 59.1% of rheumatologists, and 73.3% of orthopaedic surgeons. Strong opioids were mostly reserved as third-line treatment. Although treatment effectiveness post-CDC guidelines was not assessed, perceptions of efficacy and quality of life with opioids significantly differed across specialties, whereas perceptions of safety, convenience/acceptability and costs did not. Physicians generally agreed on the barriers to opioid prescribing, with fear of addiction and drug abuse being the most important. Across specialties, physicians reported decreased opioid prescribing for OA, irrespective of OA severity, and in most cases attributed changes in prescribing to the CDC guideline.
KW - addiction
KW - centers for disease control and prevention
KW - prescription analgesic
KW - real-world clinical practice
KW - tramadol
KW - treatment guidelines
KW - treatment patterns
UR - http://www.scopus.com/inward/record.url?scp=85146773890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146773890&partnerID=8YFLogxK
U2 - 10.3390/jcm12020589
DO - 10.3390/jcm12020589
M3 - Article
C2 - 36675516
AN - SCOPUS:85146773890
SN - 2077-0383
VL - 12
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 2
M1 - 589
ER -